Mathieu Varache1, Lydia C Powell1, Olav A Aarstad2, Thomas L Williams3, Margot N Wenzel3, David W Thomas1, Elaine L Ferguson1. 1. Advanced Therapies Group, Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences , Cardiff University , Heath Park , Cardiff CF14 4XY , U.K. 2. Department of Biotechnology and Food Sciences , Norwegian University of Science and Technology , Trondheim 7491 , Norway. 3. School of Chemistry , Cardiff University , Main Building, Park Place , Cardiff CF10 3AT , U.K.
Abstract
Polymer masked-unmasked protein therapy (PUMPT) uses conjugation of a biodegradable polymer, such as dextrin, hyaluronic acid, or poly(l-glutamic acid), to mask a protein or peptide's activity; subsequent locally triggered degradation of the polymer at the target site regenerates bioactivity in a controllable fashion. Although the concept of PUMPT is well established, the relationship between protein unmasking and reinstatement of bioactivity is unclear. Here, we used dextrin-colistin conjugates to study the relationship between the molecular structure (degree of unmasking) and biological activity. Size exclusion chromatography was employed to collect fractions of differentially degraded conjugates and ultraperformance liquid chromatography-mass spectrometry (UPLC-MS) employed to characterize the corresponding structures. Antimicrobial activity was studied using a minimum inhibitory concentration (MIC) assay and confocal laser scanning microscopy of LIVE/DEAD-stained biofilms with COMSTAT analysis. In vitro toxicity of the degraded conjugate was assessed using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. UPLC-MS revealed that the fully "unmasked" dextrin-colistin conjugate composed of colistin bound to at least one linker, whereas larger species were composed of colistin with varying lengths of glucose units attached. Increasing the degree of dextrin modification by succinoylation typically led to a greater number of linkers bound to colistin. Greater antimicrobial and antibiofilm activity were observed for the fully "unmasked" conjugate compared to the partially degraded species (MIC = 0.25 and 2-8 μg/mL, respectively), whereas dextrin conjugation reduced colistin's in vitro toxicity toward kidney cells, even after complete unmasking. This study highlights the importance of defining the structure-antimicrobial activity relationship for novel antibiotic derivatives and demonstrates the suitability of LC-MS to aid the design of biodegradable polymer-antibiotic conjugates.
Polymer masked-unmasked protein therapy (PUMPT) uses conjugation of a biodegradable polymer, such as dextrin, hyaluronic acid, or poly(l-glutamic acid), to mask a protein or peptide's activity; subsequent locally triggered degradation of the polymer at the target site regenerates bioactivity in a controllable fashion. Although the concept of PUMPT is well established, the relationship between protein unmasking and reinstatement of bioactivity is unclear. Here, we used dextrin-colistin conjugates to study the relationship between the molecular structure (degree of unmasking) and biological activity. Size exclusion chromatography was employed to collect fractions of differentially degraded conjugates and ultraperformance liquid chromatography-mass spectrometry (UPLC-MS) employed to characterize the corresponding structures. Antimicrobial activity was studied using a minimum inhibitory concentration (MIC) assay and confocal laser scanning microscopy of LIVE/DEAD-stained biofilms with COMSTAT analysis. In vitro toxicity of the degraded conjugate was assessed using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. UPLC-MS revealed that the fully "unmasked" dextrin-colistin conjugate composed of colistin bound to at least one linker, whereas larger species were composed of colistin with varying lengths of glucose units attached. Increasing the degree of dextrin modification by succinoylation typically led to a greater number of linkers bound to colistin. Greater antimicrobial and antibiofilm activity were observed for the fully "unmasked" conjugate compared to the partially degraded species (MIC = 0.25 and 2-8 μg/mL, respectively), whereas dextrin conjugation reduced colistin's in vitro toxicity toward kidney cells, even after complete unmasking. This study highlights the importance of defining the structure-antimicrobial activity relationship for novel antibiotic derivatives and demonstrates the suitability of LC-MS to aid the design of biodegradable polymer-antibiotic conjugates.
Entities:
Keywords:
Gram-negative bacteria; colistin; infection; mass spectrometry; polymer therapeutics
The
emergence of antibiotic-resistant bacteria represents a major
global health threat and a significant clinical and societal challenge.
Of particular concern is the rapidly increasing resistance rate of
many Gram-negative bacterial pathogens, which has been mirrored by
a decrease in research and development of new antibiotic compounds.[1] In 2018, the World Health Organization (WHO)
published a list of pathogens posing the greatest threat to human
health.[2] The most critical pathogen group
includes Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae (which
includes Klebsiella pneumoniae and Escherichia coli) because of high levels of drug
resistance and severity of infection in hospitals, nursing homes,
and among critically ill and elderly patients.Although progress
remains to be made in the development of new
classes of antibiotics, older “drugs of last resort”
such as colistin are increasingly being employed[3,4] as,
despite higher incidences of toxicity and significant long-term complications,
they have retained antimicrobial efficacy. Colistin (also known as
polymyxin E) is a cationic peptide from the polymyxin family of antibiotics.
It was isolated from Bacillus colistinus in 1947 and has been on the market as a treatment for Gram-negative
bacterial infections since 1950.[5] Several
years later, however, reports of dose-limiting nephro- and neurotoxicity
forced clinicians to cease using this potent antibiotic.[6,7] Colistin comprises a cyclic heptapeptide and tripeptide side chain
acylated at the N-terminus by a fatty acid. Commercially available
colistin contains at least 30 different components, 13 of which have
been isolated and identified.[8,9] The major components
are colistin A (polymyxin E1) and colistin B (polymyxin E2) which,
together, account for more than 85% of the total weight of the raw
material (Figure A).[10] The two substances differ in the length of the
fatty acid side chain by one methylene group.
Figure 1
(A) Chemical structure
of the two subgroups of colistin. (B) Schematic
representation of the degradation of the dextrin–colistin conjugate
by α-amylase. Amylase hydrolyzes dextrin at random locations
along its chain to yield the disaccharides maltose and iso-maltose,
resulting in a decrease in dextrin’s chain length by xd-glucose units, where n is
the DP of the polymer.
(A) Chemical structure
of the two subgroups of colistin. (B) Schematic
representation of the degradation of the dextrin–colistin conjugate
by α-amylase. Amylase hydrolyzes dextrin at random locations
along its chain to yield the disaccharides maltose and iso-maltose,
resulting in a decrease in dextrin’s chain length by xd-glucose units, where n is
the DP of the polymer.We have recently employed polymer masked–unmasked
protein
therapy (PUMPT) to deliver colistin conjugated to dextrin using nonspecific
carbodiimide conjugation chemistry.[11] PUMPT
uses conjugation of a biodegradable polymer, such as dextrin, hyaluronic
acid, or poly(l-glutamic acid), to mask a protein or peptide’s
activity.[12−14] Following intravenous administration, colistin is
expected to localize and accumulate within sites of inflammation by
the enhanced permeability and retention (EPR) effect,[11,15,16] where the antibiotic can be released
from the conjugate via amylase-triggered degradation of dextrin. Reinstatement
of the payload’s biological activity may be controlled by employing
dextrins of different molecular weights and degrees of modification,
tailoring the conjugation chemistry and by the degree of inflammation/enzymatic
activity at the “target” site.[11,14] In contrast to the administration of growth factors to induce healing,[17] anti-infective therapy requires rapid delivery
of the antibacterial payload at the site of infection. Previous studies
of dextrin–colistin conjugates have attempted to optimize dextrin–colistin
conjugate’s release kinetics by varying the molecular weight
and degree of succinoylation of dextrin.[11] Ferguson et al. demonstrated that conjugates containing 7500 g/mol
dextrin with 1 mol % succinoylation resulted in the release of ∼80%
of the bound drug within 48 h when incubated with physiological levels
of amylase (100 IU/L).[11] Dextrin–colistin
conjugates exhibited reduced in vitro and in vivo toxicity and prolonged
plasma half-life (dextrin–colistin t1/2 = 135 min, colistin t1/2 = 53 min).[11] Sustained, concentration-dependent killing of A. baumannii was observed in an in vitro pharmacokinetic–pharmacodynamic
model, and unmasking of the conjugate in human wound exudate was confirmed.[15] The conjugates also demonstrated antibacterial
activity (against Gram-negative pathogens) similar to the commercially
available prodrug, colistin methanesulfonate (CMS, Colomycin). Interestingly,
however, even after complete unmasking, antimicrobial activity remained
lower than the unmodified drug; being more pronounced in conjugates
containing dextrin with higher degrees of modification.[11]Whilst the concept of PUMPT is well established,
the degree to
which unmasking must occur to completely reinstate the payload’s
bioactivity has not yet been determined. In the dextrin–colistin
conjugate model, α-amylase randomly cleaves the dextrin backbone,
yielding the disaccharides, maltose and iso-maltose.[18] The dextrin is, however, attached to colistin via a nondegradable
amide bond; therefore, even after complete degradation of dextrin,
substituent groups will remain attached to colistin (Figure B). Their presence may explain
the inability to completely reinstate antibiotic activity following
exposure to amylase. In the present work, we hypothesize that these
remaining substituent groups, particularly the number of glucose units,
may strongly affect antimicrobial properties of the unmasked conjugate.
Here, the chemical composition of differentially degraded dextrin–colistin
conjugates is reported and related to the species’ biological
activity and in vitro toxicity, to determine the optimal extent of
conjugate unmasking that is required to achieve maximal antimicrobial
activity.
Materials and Methods
Materials
Type I dextrin from corn
(Mw = 7500 g/mol), colistin sulfate, α-amylase
from human saliva, N-hydroxysulfosuccinimide (sulfo-NHS),
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT),
bicinchoninic acid (BCA) solution, and dimethyl sulfoxide (DMSO) maltose
oligomers [degree of polymerization (DP) 2, 3, 6, and 7] were purchased
from Sigma-Aldrich (Poole, U.K.). 1-Ethyl-3-(3-(dimethylamino)propyl
carbodiimide hydrochloride) (EDC) was acquired from Pierce (Rockford,
USA). Disodium hydrogen phosphate, potassium dihydrogen phosphate,
potassium chloride, 4-dimethylaminopyridine, and sodium chloride were
from Fisher Scientific (Loughborough, U.K.). Pullulan gel filtration
standards (Mw = 11 800–210 000
g/mol) were purchased from Polymer Laboratories (Church Stretton,
U.K.). Unless otherwise stated, all chemicals were of analytical grade
and used as received. All solvents were of general reagent grade (unless
stated) and were from Fisher Scientific (Loughborough, U.K.).
Bacterial Culture
Bacterial colonies
were grown on blood agar supplemented with 5% horse blood, and liquid
cultures were suspended in a tryptone soya broth for overnight culture
or Mueller–Hinton broth (MHB) for minimum inhibitory concentration
(MIC) determination (Oxoid; Basingstoke, U.K.). Antibacterial activity
was screened against an E. coli clinical
isolate (V5) provided by Professor Timothy Walsh (Department of Infection
and Immunity, Cardiff University). Its known relevant genotype and
origin have been described by Khan et al.[19]
Cell Culture
Human kidney proximal
tubule cells (HK-2) were obtained from ATCC (Manassas, USA) and screened
to be free of mycoplasma contamination before use. Keratinocyte serum-free
medium (K-SFM) with l-glutamine, epidermal growth factor
(EGF), bovine pituitary extract (BPE), and 0.05% w/v trypsin-0.53
mM ethylenediaminetetraacetic acid were obtained from Invitrogen Life
Technologies (Paisley, U.K.).
Synthesis
of Dextrin–Colistin Conjugates
Dextrin–colistin
conjugates were synthesized using EDC and
sulfo-NHS and characterized as previously described.[11] The dextrin–colistin conjugate used in these studies
contained dextrin (Mw = 7500 g/mol; DP
= 50) with 1 mol % succinoylation, a colistin content of 7.6% w/w
(by BCA assay) (equivalent to 2 dextrin chains per colistin), and
a molecular weight of 10 000 g/mol (by gel permeation chromatography
with pullulan standards, Mw/Mn = 1.5). Free colistin content, analyzed by fast protein
liquid chromatography (LC), was determined as <4%. The characteristics
of dextrin–colistin conjugates used to analyze the effect of
succinoylation on the degree of peptide modification are summarized
in Table S1.
Amylase
Degradation of Dextrin–Colistin
Conjugates
Unmasked dextrin–colistin conjugates were
prepared by incubation of the dextrin–colistin conjugate (3
mg/mL colistin base in PBS, pH 7.4) with amylase (100 IU/L) for up
to 48 h at 37 °C. Samples were subsequently lyophilized and stored
at −20 °C prior to analysis.
Analysis
of Masked–Unmasked Conjugates
and Fractionation by SEC
Samples (10–100 mg) were
dissolved in 4 mL of 0.1 M ammonium acetate (pH 6.9, 0.22 μm
filter-sterilized) and then manually injected into an 8 mL sample
loop. The size exclusion chromatography (SEC) system consisted of
3 serially connected HiLoad Superdex 30 columns (2.6 × 60 cm),
a Shimadzu LC-10 AD vp pump, a Shimadzu SPD-10 AV vp UV-detector (215
nm), and a Shodex RI-101 refractive index detector. Data were collected
with an Adam view 4561 converter and a 4017P input module. Samples
were eluted at a flow rate of 0.8 mL/min and fractions collected every
50 min between 400 and 800 min and stored at −20 °C until
lyophilization. Lyophilized samples were dissolved in MQ water and
then freeze-dried (×5) to remove ammonium acetate. Total protein
content of the degraded fractions was determined by the BCA assay
using colistin standards.
Characterization of the
Collected Fractions
by LC–Mass Spectrometry
Colistin (10 μg/mL,
5 μL) and fractions (1 mg/mL total weight, 5 μL) were
analyzed on a Synapt G2-Si quadrupole time-of-flight (QTOF) mass spectrometer
(Waters, UK) operating in the positive electrospray ionization mode,
coupled to an ACQUITY H-Class UPLC system (Waters, UK). Separation
was performed using an ACQUITY UPLC CSH C18 column (300 Å, 1.7
μm, 2.1 × 100 mm, Waters) held at 40 °C with a flow
rate of 0.3 mL/min. A multistep gradient method using 98% A for 2
min followed by a linear gradient to 50% A for 18 min, where A is
water (0.1% formic acid) and B is acetonitrile (0.1% formic acid).
Analysis of Unmasked Conjugate by High-Performance
Anion Exchange Chromatography with Pulsed Amperometric Detection
Samples (0.1–1 mg/mL total weight) were analyzed using a
Dionex ICS-5000+ ion chromatography system (Thermo Scientific, Oslo,
Norway) with an electrochemical detector fitted with a nondisposable
gold working electrode. Samples were injected via a 25 μL loading
loop. Separation was performed using a CarboPac PA-100 (4 × 50
mm, Dionex) guard column and CarboPac PA-100 (4 × 250 mm, Dionex)
analytical column connected held at 24 °C with a flow rate of
1 mL/min. Analysis was performed using isocratic 100 mM sodium hydroxide
and a linear sodium acetate gradient from 10 to 610 mM in 90 min.
A Carboquad waveform was used for detection. Data were collected and
processed using Chromeleon 7.2 software.
Measurement
of Antimicrobial Activity
Antimicrobial activity was measured
using broth microdilution in
a standard MIC assay.[20]E. coli strain, V5, was suspended in MHB (100 μL,
1 to 5 × 104 CFU/mL) and incubated in 96-well microtiter
plates in serial twofold dilutions of the test compounds. To prepare
initial dilutions, samples were dissolved in PBS at 50 μg/mL
(colistin base) and then diluted in MHB to a starting concentration
of 16 μg/mL colistin. Experiments were performed in triplicate
and expressed as the modal value.
Bacterial
Growth Curves
The pharmacokinetic
profile of individual fractions was studied against E. coli. Colistin and the derived fractions (with
4 μg/mL starting colistin concentration) were added to 96-well
microtiter plates in serial twofold dilutions. Plates were wrapped
in Parafilm M and placed in a microtiter plate reader at 37 °C;
bacterial growth was assessed by measuring absorbance (at 600 nm),
hourly, for 48 h. The absorbance values were expressed as mean ±
standard deviation (SD) (n = 3).
Confocal Laser Scanning Microscopy and COMSTAT
Analysis
The direct effects of the analytes were studied
using confocal laser scanning microscopy (CLSM) imaging. E. coli biofilms were grown in Grenier 96-well glass-bottomed
plates in MHB ± colistin or degraded fractions. A 1:10 inoculum
of E. coli overnight culture (1 ×
107 CFU/mL) was used, and plates were incubated at 37 °C
for 24 h. The supernatant was carefully removed from the plates, and
the biofilms were stained with LIVE/DEAD (Baclight Bacterial Viability
Kit, Molecular Probes) for 10 min before imaging using a Leica SP5
CLSM. CLSM images were achieved with a ×63 lens (oil) and a step
size of 0.79 μm. The resultant CLSM z-stack images were analyzed
using COMSTAT image analysis software for quantification of three-dimensional
biofilm structures through measurement of biomass, mean biofilm thickness,
roughness coefficient, and DEAD/LIVE bacterial ratio.[21] Statistical calculations were performed using Minitab v.14
(Minitab, State College, PA). To determine significant differences
for pair-wise comparisons, the nonparametric data were analyzed using
the Mann–Whitney test. A p value < 0.05
was considered statistically significant.
In Vitro
Cytoxicity
An MTT assay
was used to assess cell viability in a human kidney (HK-2) cell line
(72 h incubation). HK-2 cells (passages P15 to P20) were seeded into
sterile 96-well microtiter plates (2.5 × 104 cells/mL)
in 0.1 mL/well of media (K-SFM) containing l-glutamine, EGF,
and BPE and allowed to adhere for 24 h. The medium was then removed,
and test compounds were added to the wells. To study the effect of
colistin sulfate, fraction F8, and intact dextrin–colistin
conjugate on cell viability, complete media were supplemented with
a range of different concentrations of each. After a further 67 h
incubation, MTT (20 μL of a 5 mg/mL solution in PBS) was added
to each well and incubated for a further 5 h. The medium was then
removed, and the precipitated formazan crystals solubilized by the
addition of optical grade DMSO (100 μL). After 30 min, the absorbance
of each well was measured at 540 nm using a microtiter plate reader.
Cell viability was expressed as a percentage of the viability of untreated
control cells and expressed as mean ± standard error of the mean
(SEM) (n = 18). Evaluation of significance was achieved
using a two-way analysis of variance (ANOVA) followed by Bonferroni
post hoc tests that correct for multiple comparisons. All statistical
calculations were performed using a GraphPad Prism, version 6.0h for
Macintosh, 2015.
Results
Chemical
Characterization of Degraded Fractions
SEC-RI of the dextrin–colistin
conjugate after amylase unmasking
showed a decrease of the peak corresponding to the conjugate (400–750
min) (Figure A). This
was mirrored by the appearance of a peak corresponding to a species
with a molecular weight close to that of colistin (retention time
∼760 min), which was also observed by SEC-UV (Figure B). SEC-RI revealed peaks corresponding
to water, ammonium acetate salts, and glucose (∼1000 min),
whereas added sodium chloride and phosphate salts eluted at ∼1050
min. Several oligosaccharides, released by the degradation of dextrin,
were also observed (850–950 min). High-performance anion exchange
chromatography with pulsed amperometric detection (HPAEC-PAD) revealed
that the most intense peaks corresponded to maltose (DP = 2) and maltotriose
(DP = 3) (Figure S1). Therefore, assuming
that the intensity of the peaks observed by HPAEC-PAD mirrored those
observed by SEC-RI, the two major peaks observed by the latter at
926 and 951 min were identified as maltotriose and maltose, respectively.
Analysis of the protein content of individual fractions revealed that
fraction F8 (750–800 min retention time) contained the highest
amount of colistin (38.8% w/w) compared to fractions F1–7 (400–750
min retention time, 2.1–5.5% w/w) (Table ).
Figure 2
SEC chromatograms of colistin (black), dextrin–colistin
conjugate (blue), and α-amylase-treated (48 h at 37 °C)
dextrin–colistin conjugate (red) by (A) RI detection and (B)
UV detection (λ = 215 nm). Collected fractions are shown in
orange.
Table 1
Protein Content and
Antimicrobial
Activity (Mode MIC, n = 3) of Colistin Sulfate and
Collected Fractionsa
fractions
protein content (% w/w)
MIC (μg/mL)
F1
2.1
4
F2
3.2
4
F3
2.9
8
F4
3.2
8
F5
3.4
4
F6
3.9
4
F7
5.5
2
F8
38.8
0.25
colistin
100
1.95 × 10–3
Data is expressed
as mode (n = 3); MIC value represents equivalent
colistin base concentration
of fractions.
SEC chromatograms of colistin (black), dextrin–colistin
conjugate (blue), and α-amylase-treated (48 h at 37 °C)
dextrin–colistin conjugate (red) by (A) RI detection and (B)
UV detection (λ = 215 nm). Collected fractions are shown in
orange.Data is expressed
as mode (n = 3); MIC value represents equivalent
colistin base concentration
of fractions.LC–mass
spectrometry (MS) analysis revealed distinct structural
differences between individual fractions and unmodified colistin (Table S2). Figure illustrates ultraperformance liquid chromatography
(UPLC) chromatograms and the corresponding mass spectra are shown
in Figures S2–S5. Colistin’s
UPLC chromatogram revealed two main peaks at 5.6 and 6.4 min, corresponding
to colistin B and colistin A, respectively (Figure A). The chromatogram for fraction F8 contained
a peak at 1.2 min, corresponding to oligosaccharides with DP 7–13
(1200–2100 g/mol) (Figure B). MS analysis of the peak revealed an intense peak
at m/z 839.22, corresponding to
an oligosaccharide with DP10 (Figure S3). In addition, the UPLC chromatogram of fraction F8 revealed multiple
peaks, corresponding to colistin A and B attached to one linker ±
H2O (7.2–8.6 min) and colistin A and B bound to
two linkers −1 or 2 H2O (8.9–10.4 min) (Figure B). Colistin A and
B bound to two linkers without the loss of H2O were not
observed. Interestingly, peaks corresponding to the same molecular
mass were observed at different retention times. The UPLC chromatogram
for fraction F7 contained a peak at 1.1 min, corresponding to dehydrated
oligosaccharides with DP 7–18 (1200–2900 g/mol) (Figure C). The MS analysis
of the peak revealed the most intense peak at m/z 1135.38, which corresponded to an oligosaccharide with
DP14. In addition, peaks in the UPLC chromatogram between 7.5 and
7.9 min were observed, which corresponded to colistin B attached to
1–6 glucose units via a single linker ± H2O.
Similarly to fractions F7 and F8, the UPLC chromatogram for fraction
F6 contained a peak at 1.1 min, which corresponded to oligosaccharides
with DP 13–22 (2100–3600 g/mol) (Figure D). The most intense peak by MS was detected
at m/z 1468.44, corresponding to
DP18. A peak was also observed at 7.9 min, which corresponded to colistin
B attached to 6–8 glucose units via a single linker and colistin
A attached to 6–13 glucose units via a single linker. Sharp
peaks observed between 3.5 and 6.5 min and above 9.5 min were impurities.
UPLC–QTOF-MS
chromatograms (base peak intensity) of (A)
colistin (10 μg/mL), (B) F8 (1 mg/mL), (C) F7 (1 mg/mL), and
(D) F6 (1 mg/mL).LC–MS analysis
of unfractionated amylase-degraded dextrin–colistin
conjugates with different degrees of succinoylation (1.0, 2.5, and
7.5 mol %) revealed structural differences in released species (Figures S6 and S7, Table S3). Whereas the UPLC chromatogram for dextrin–colistin
conjugates containing 1.0 mol % succinoylated dextrin contained considerably
more colistin A and B bound to only one linker, the UPLC chromatogram
for the degraded conjugate containing 2.5 mol % succinoylated dextrin
revealed peaks corresponding to an almost equal proportion of colistin
A and B bound to one (6.8–8.8 min) or two (8.8–11 min)
linkers −1 to 2 H2O. Smaller peaks corresponding
to colistin A and B bound to 3 linkers −1 to 3 H2O (11–13.4 min) were also observed. When the degree of dextrin
succinoylation was increased to 7.5 mol %, the intensity of peaks
corresponding to colistin A and B bound to 2 or 3 linkers increased.
This was mirrored by a decrease in the intensity of peaks corresponding
to colistin A and B with a single linker attached. In all cases, the
maximum number of water molecules lost from the species was equal
to the number of linkers attached to colistin; species with the greatest
loss of water appeared later in the UPLC chromatogram.
Biological Activity of Degraded Fractions
All of the
fractions analyzed exhibited lower antimicrobial activity
than unmodified colistin (7–12 log-fold reduction in MIC),
which varied between fractions. Antimicrobial activity was significantly
higher for fraction F8, corresponding to fully unmasked colistin,
than fractions corresponding to colistin with oligosaccharide chains
attached (up to 5 log-fold reduction in MIC) (Table ). The MIC value of the intact conjugate
was 2 μg/mL, which is equivalent to the MIC of the bound fractions
(from F1 to F7). Whilst fraction F8 (at 1/4 MIC, 0.0625 μg/mL
colistin equiv) significantly delayed E. coli growth (by up to 10 h), fractions F6 and F7 showed limited effect
on bacterial growth, even at 1/2 MIC (1 and 2 μg/mL colistin
equiv, respectively) (Figure ). Bacterial lag time in the presence of colistin at 1/4 and
1/2 MIC (4.88 × 10–3 and 9.77 × 10–3 μg/mL colistin equiv, respectively) was at
least half that of bacteria grown in the presence of fraction F8 at
1/4 and 1/2 MIC (0.0625 and 0.125 μg/mL colistin equiv, respectively)
(Figure c). Observations
in the planktonic culture systems were reflected in the effects of
the fractions in bacterial biofilm systems. Fraction F8, at 2×
MIC (0.5 μg/mL colistin equiv), effectively inhibited biofilm
formation (Figure A). COMSTAT analysis of CLSM images revealed that this was associated
with a significant reduction in biofilm biomass and thickness and
a significant increase in roughness coefficient and bacterial cell
death (p < 0.05, vs control; Figure B). Whereas fraction F7, at
the same concentration, had no significant effect on biofilm formation,
fraction F6 caused a significant increase in biofilm thickness and
biomass (p < 0.05, vs control). When biofilms
were grown in the presence of fractions at the MIC observed for F8
(0.25 μg/mL colistin equiv), no significant effect on biofilm
formation was observed in the presence of fractions F8 and F7, whereas
treatment with fraction F6 caused a significant increase in biofilm
biomass and thickness, mirrored by a decrease in roughness coefficient
(Figure S8) (p < 0.05,
vs control). In comparison, colistin at 0.25 and 0.5 μg/mL (equivalent
to fraction F8’s MIC and 2× MIC, respectively) caused
complete inhibition of biofilm formation, whereas no effect on biofilm
formation was observed when biofilms were grown at 0.002 and 0.004
μg/mL (equivalent to colistin’s MIC and 2× MIC)
(Figure C,D). Although
antibacterial activity of the fully unmasked colistin was lower than
the parent drug, in vitro cytotoxicity of fraction F8 was statistically
less cytotoxic than both, unmodified colistin and intact dextrin–colistin
conjugate in human kidney cells (Figure ).
Figure 4
Bacterial growth curves for E.
coli (48 h) in the presence of colistin sulfate and
fractions F6, F7,
and F8 at (A) 1/2 MIC and (B) 1/4 MIC (colistin base) (mean ±
SD; n = 3). Corresponding lag times are indicated
next to the figures. Panel (C) shows bacterial growth lag time, determined
using an absorbance threshold of 0.1.
Figure 5
Biofilm formation assay showing LIVE/DEAD (green and red colors,
respectively) stained CLSM images of E. coli biofilms (aerial and side view, scale bar = 40 μm) grown for
24 h in the presence of (A) fractions F6, F7, and F8 at 0.5 μg/mL
colistin base (equivalent to 2× fraction F8’s MIC) and
(C) colistin sulfate at 0.25 and 0.5 μg/mL colistin base, MIC
and 2× MIC. COMSTAT image analysis of biofilm CLSM z-stack images
for (B) fractions and (D) colistin sulfate. Data represent mean ±
SD; n = 3. Significant difference is indicated by
*, where *p < 0.05, compared to untreated control.
Figure 6
In vitro cytotoxicity of colistin sulfate, fraction
F8, and intact
dextrin–colistin conjugate (1 mol % succinoylation). Cell viability
was assessed by MTT assay of HK-2 cells (72 h incubation) at 50, 100,
and 250 μg/mL colistin base. Data are expressed as mean % untreated
control ± SEM, n = 18. Significant difference
is indicated by *, where **p < 0.01 and ***p < 0.001. For the conjugate, errors bars are too small
to be visible.
Bacterial growth curves for E.
coli (48 h) in the presence of colistin sulfate and
fractions F6, F7,
and F8 at (A) 1/2 MIC and (B) 1/4 MIC (colistin base) (mean ±
SD; n = 3). Corresponding lag times are indicated
next to the figures. Panel (C) shows bacterial growth lag time, determined
using an absorbance threshold of 0.1.Biofilm formation assay showing LIVE/DEAD (green and red colors,
respectively) stained CLSM images of E. coli biofilms (aerial and side view, scale bar = 40 μm) grown for
24 h in the presence of (A) fractions F6, F7, and F8 at 0.5 μg/mL
colistin base (equivalent to 2× fraction F8’s MIC) and
(C) colistin sulfate at 0.25 and 0.5 μg/mL colistin base, MIC
and 2× MIC. COMSTAT image analysis of biofilm CLSM z-stack images
for (B) fractions and (D) colistin sulfate. Data represent mean ±
SD; n = 3. Significant difference is indicated by
*, where *p < 0.05, compared to untreated control.In vitro cytotoxicity of colistin sulfate, fraction
F8, and intact
dextrin–colistin conjugate (1 mol % succinoylation). Cell viability
was assessed by MTT assay of HK-2 cells (72 h incubation) at 50, 100,
and 250 μg/mL colistin base. Data are expressed as mean % untreated
control ± SEM, n = 18. Significant difference
is indicated by *, where **p < 0.01 and ***p < 0.001. For the conjugate, errors bars are too small
to be visible.
Discussion
In the last decades, biodegradable polymers have grown in popularity
because of their ability to reduce the bioactive’s antigenicity,
extend circulatory half-life, and release the payload by degradation
of the polymer at the target site.[22−24] Biodegradable polymers
have the added advantage of enabling the use of much larger polymers
because they are not limited to the renal threshold. Our previous
studies, using dextrin–colistin conjugates, suggested that
colistin’s antibacterial activity is greatest when it was attached
to shorter chains of dextrin with minimal modification;[11] however, the composition of the active species
and the extent to which the polymer must be degraded to restore biological
activity has not been defined in any studies relating to PUMPT.[12] An accurate definition of the “bound”
and “free” species and identification of the structure–activity
relationship are needed to develop and validate a chromatographic
detection method to assess the pharmacokinetics and tissue distribution
of dextrin–colistin conjugates. In previous studies, a colistin
enzyme-linked immunosorbent assay kit was used to measure the pharmacokinetics;
however, this method is unable to distinguish between “free”
(active) and dextrin-bound (inactive) colistin.[11] In this study, fractionation of degraded dextrin–colistin
conjugate by SEC followed by analysis using LC–MS and biological
assays has been used to specifically determine the molecular structure
of the active species.
Chemical Characterization
SEC-RI
of the dextrin–colistin conjugate after amylase unmasking was
successfully used to obtain fractions containing saccharides and colistin-based
species with different molecular weights. Characterization of the
molecular structure of low molecular weight derivatized peptides and
conjugates is complex, necessitating the use of highly sensitive detection
methods such as MS.[25] Because interpretation
of MS data requires deconvolution of molecular fragments, in these
studies, LC–MS was only performed on fractions corresponding
to lower molecular weight species. LC was employed instead of direct
injection as a separation of colistin-based species from released
saccharides would make identification of the species more straightforward.
Analysis of fraction F8 revealed a range of colistin-containing species,
reflecting the heterogeneous composition of the conjugates due to
nonspecific binding of dextrin to the 5 amino groups of colistin.
This is also witnessed by the presence of peaks with different retention
times corresponding to structures with the same molecular mass. This
has been described previously; poly(ethylene glycol) (PEG)–protein
positional isomers and multiple PEGylated products are common, resulting
from “nonselective” conjugation to several nucleophilic
groups (e.g., lysine residues and terminal amine) on the protein.[26,27] This has led to researchers exploring site-selective conjugation
methods.[28,29]The presence of linkers attached to
colistin’s amino groups increased its hydrophobicity. Thus,
the species with more linkers attached appeared later in the UPLC
chromatogram. Here, we showed that with increasing degree of succinoylation,
the number of linkers bound to colistin also increased. Previously,
we used a ninhydrin assay to quantify the number of free amino groups
following conjugation, which estimated that each colistin molecule
was attached to dextrin via ∼3 NH2 groups, regardless
of the succinoylation rate.[11] However,
this method is unlikely to be as precise as LC–MS used here.
Typically, increasing the extent of bioactive modification will reduce
the bioactive’s antigenicity and extend its circulation half-life;
however, this may be accompanied by a loss of the bioconjugate’s
pharmacological activity.[30] Our observations
here may explain the reduced antimicrobial activity of conjugates
containing dextrins with a higher degree of succinoylation, observed
in our previous studies,[11] as well as that
of other researchers.[12]High-performance
LC has previously been used to investigate the
stability of commercial forms of the colistin prodrug, CMS, which
readily undergoes random hydrolysis of the five sulfomethyl groups
in aqueous solutions, resulting in up to 32 products.[31−33] In the same way as dextrin conjugation decreases colistin’s
in vitro antibacterial potency, so too does sulfomethylation.[34−36] CMS is an inactive prodrug of colistin.[37] However, although amylase-triggered release of colistin released
up to 80% free drug after 24 h in vitro,[11] conversion efficiency of CMS to colistin in the same period varies
from 23 to 80% in vitro (in water, phosphate buffer and human plasma
at 37 °C),[11,31] whereas only 30% of the prodrug
is converted to colistin in vivo, as the remaining 70% of the CMS
dose administered is excreted intact in the urine.[31] In contrast, colistin is not cleared renally and dextrin–colistin
conjugates have demonstrated an extended plasma half-life following
IV administration to rats.[11]
Biological Activity
Colistin is a
highly potent antibiotic that has retained activity against most Gram-negative
MDR strains.[38−41] In previous studies, MIC assays showed greater antimicrobial activity
from dextrin–colistin conjugates containing colistin with fewer
and shorter chains of minimally modified dextrin attached.[11] Similarly, Zhu et al. observed reduced antibiotic
activity from bi-PEGylated colistin, compared to the mono-PEGylated
antibiotic, which was attributed to the former’s larger molecular
weight and slower colistin release rate.[42] Previously, pre-incubation of dextrin–colistin conjugates
with physiological concentrations of amylase only reduced the MIC
value by 1 log-fold, compared to the untreated conjugate;[11] however, these studies used a crude mixture
of degraded conjugate, composed of a heterogeneous mixture of differentially
degraded conjugates, which may mask the effect of the active species.
Indeed, these studies showed a clear distinction in antimicrobial
activity of fraction F8 and the larger fractions of degraded conjugate
(which had an equivalent MIC to the intact dextrin–colistin),
suggesting that complete degradation of dextrin is required to reinstate
maximal antibiotic activity. Chemical characterization of fraction
F8 showed that colistin retained a linker group attached to it, even
after complete polymer degradation. This is in contrast to CMS, where
complete hydrolysis of all of the sulfomethyl groups forms the parent
drug, colistin. Because colistin’s interaction with anionic
lipopolysaccharide molecules on the outer membrane of Gram-negative
bacteria is mediated via its 5 amine groups[43] and dextrin is conjugated to colistin via at least one of these
groups, it is not surprising that the antibacterial activity is reduced
by the presence of a linker group at this site. Interestingly, of
the 10 novel polymyxin derivatives that have been shown to be more
effective than conventional polymyxins in animal infection models,
8 of them retain all five Dab residues, confirming the importance
of the positively charged amine groups for antimicrobial activity.[44] A similar inability to completely recover the
bioactive’s biological activity (following enzymatic polymer
degradation) has also been observed when hyaluronan was conjugated
to EGF, using similar conjugation chemistry;[13] a finding attributed to the presence of oligosaccharides attached
to the lysine residue close to EGF’s receptor-binding domain.
In previous antibiotic conjugation models, in an attempt to maximize
antibiotic activity, Zhu et al. used a labile ester linker in their
mono-PEGylated colistin to facilitate release of drug that was chemically
identical to unmodified colistin and retained similar activity to
the native peptide.[42] Here, treatment with
fraction F6 counter-intuitively induced significant biofilm growth,
presumably because of the bacteria using the longer oligosaccharide
chains as a carbon- and energy source.In practice, systemic
administration of colistin may be restricted by dose-limiting nephrotoxicity,
which occurs due to reabsorption and accumulation of colistin in renal
tubular cells.[11] Previous studies showed
that dextrin conjugation reduced colistin’s in vitro cytotoxicity
toward human kidney proximal tubule (HK-2) cells, with around a four–fivefold
improved IC50 concentration.[11] Even after amylase-unmasking of dextrin–colistin conjugates,
cytotoxicity remained similar to the intact conjugate and less than
colistin sulfate. Given the heterogeneous composition of this crude
mixture, it was important in the current study to test the cytotoxicity
of the individual fractions. Whilst the finding that fraction F8 was
significantly less toxic in vitro than the intact dextrin–colistin
conjugate appeared surprising, Zhu et al. demonstrated that colistin
attached to a single PEG chain failed to induce histological renal
damage in vivo at 40 mg colistin equiv/kg, but the presence of 2 PEG
chains, however, resulted in renal tubular injury.[42] The authors attributed this difference in nephrotoxicity
to the complex and different renal handling mechanisms of the mono-
and di-PEGylated colistin. Here, the reduced toxicity observed in
fraction F8, compared to the intact dextrin–colistin conjugate,
may reflect altered uptake and accumulation by HK-2 cells because
of the oligosaccharides attached to colistin.
Future
Perspectives
Our ultimate
goal is to develop and validate a chromatographic detection method
to study degradation and biodistribution of dextrin–colistin
conjugates following in vivo administration by analysis of serum and
other biological samples (e.g., macerated organs). Method development
is ongoing but challenging because the chemical diversity of the released
species precludes the use of reversed-phase separation and the low
absorbance of colistin necessitates the use of a derivatization method
that will not be affected by residual saccharide moieties. The results
of these structure–activity relationship studies demonstrate
that complete unmasking of colistin is required for maximum antibiotic
activity. Because the smallest fractions may not localize as efficiently
to sites of infection by the EPR effect and are likely to be cleared
faster from the body, ideally, unmasking should occur predominantly
at the target site. We have previously shown that the α-amylase
activity is significantly higher in infected wound fluid compared
to that in patient-matched serum (408.4 and 60.0 IU/L, respectively),[15] which suggests that this could be feasible.
Ongoing studies are developing an in vivo mouse model to test this
hypothesis and quantify the amount of “free”/active
and “bound”/inactive colistin in biological samples.
Conclusions
This study highlights the importance
of defining the structure–antimicrobial
activity relationship for novel antibiotic derivatives. Here, we have
demonstrated that the presence of functional groups attached to colistin
significantly affects its biological activity, and this effect can
be minimized (but not fully reversed) by enzymatic degradation of
the polymer. LC–MS is a valuable tool for characterizing conjugation
patterns, which can aid in the design of biodegradable polymer–antibiotic
conjugates, as well as for studying drug distribution and disposition
in vivo.
Authors: Jian Li; Roger L Nation; John D Turnidge; Robert W Milne; Kingsley Coulthard; Craig R Rayner; David L Paterson Journal: Lancet Infect Dis Date: 2006-09 Impact factor: 25.071
Authors: Jian Li; Roger L Nation; Robert W Milne; John D Turnidge; Kingsley Coulthard Journal: Int J Antimicrob Agents Date: 2005-01 Impact factor: 5.283
Authors: Jacob F Pollock; Randolph S Ashton; Nikhil A Rode; David V Schaffer; Kevin E Healy Journal: Bioconjug Chem Date: 2012-08-23 Impact factor: 4.774
Authors: Joana Stokniene; Lydia C Powell; Olav A Aarstad; Finn L Aachmann; Philip D Rye; Katja E Hill; David W Thomas; Elaine L Ferguson Journal: Pharmaceutics Date: 2020-11-11 Impact factor: 6.321